

End point title: Number of Subjects With Sustained Reduction in Disability (SRD) Assessed by EDSS at Year 6

Statistical analysis title	Alemtuzumab Treatment CAMMS323 Extension
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	Alemtuzumab Treatment CAMMS323 Extension
Number of subjects included in analysis	235
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SRD
Point estimate	32.69
Confidence interval	
level	95%
sides	2-sided
lower limit	26.96
upper limit	39.28
Statistical analysis title	Alemtuzumab Treatment CAMMS324 Extension
Statistical analysis description	The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method.
Comparison groups	Alemtuzumab Treatment CAMMS324 Extension
Number of subjects included in analysis	321
Analysis specification	Pre-specified
Analysis type	superiority
Method	
Parameter type	Percentage with SRD
Point estimate	42.46
Confidence interval	
level	95%
sides	2-sided
lower limit	37.08
upper limit	48.28